11 Peptides Just Got Greenlit by the FDA (Here's What Changed)
A physician explains what the April 15, 2026 FDA change to the compounding lists does and does not mean, and which peptides face advisory committee review next.
With Dr. Ashley Froese (licensed physician)
Key moments
Tap a moment to play the video from there.
- 0:00What the FDA changed on April 15Froese says the FDA removed 11 peptides and 12 compounds from the category 2 list, which she describes as a compounding ban since 2023.
- 1:02Doctors went quiet on peptidesShe says the restriction made peptides hard for physicians to discuss and led some doctors to shame patients who asked about them.
- 1:48Research chemicals and the black marketFroese says most people bought peptides from sellers labeling them not for human use, and that the 2023 ban pushed demand into that market.
- 2:35Purity and testing concernsShe says some research companies did not batch test often enough and that the FDA found very low purity in some imported batches.
- 4:08Category 1 versus category 2She explains the bulk drug list as substances pharmacies may compound while the FDA evaluates them, and category 2 as flagged for risk or thin human data.
- 5:08Removal does not mean pharmacies can compoundFroese stresses that pharmacies cannot legally start compounding these on this change alone and that a pharmacy saying otherwise is a red flag.
- 5:40July 2026 committee review listShe lists the peptides and indications the advisory committee will evaluate, including BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and DSIP.
- 6:41February 2027 reviewFroese says Melanotan II, Dihexa, LL-37 and injectable GHK copper come up in February 2027, and she questions the Melanotan II inclusion.
- 7:42How an indication unlocks off-label useShe explains that approval for one indication lets a pharmacy compound a substance, after which prescribers can still use it off-label.
- 8:42Public comment docketFroese gives docket FDA-2025-N-6895, open until July 9th at regulations.gov, and says reported real-world outcomes matter to the committee.
What the video says
In this ten minute video, physician Dr. Ashley Froese explains what she says happened on April 15th, 2026, when the FDA removed 11 peptides, 12 compounds overall, from its category 2 "do not compound" list. She describes that list as the regulatory equivalent of a ban on pharmacy compounding since 2023, and says her aim is to separate what people are claiming from what actually changed.
Froese says the 2023 restriction left only a few options, such as sermorelin, PT-141, oxytocin and topical GHK copper, available from compounding pharmacies, and that many doctors stopped discussing peptides. She credits RFK Jr. with the argument that the ban pushed people toward sellers of research chemicals. In her account, some of those companies did not batch test often enough, and the FDA caught imported products with very low purity, though she notes nobody knows how common that was. She contrasts this with pharmacies, which she says must meet standards for testing and sterile compounding environments.
The central caution of the video is that removal from category 2 does not make compounding legal today. Froese says the compounds now sit in regulatory limbo, and that a pharmacy claiming otherwise is a red flag. She says the Pharmacy Compounding Advisory Committee will meet at the end of July 2026 to evaluate BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and DSIP for specific indications, with Melanotan II, Dihexa, LL-37 and injectable GHK copper reviewed in February 2027. A favorable vote, she says, would only start rulemaking and a public comment period, so months more would pass.
Froese also explains that a named indication, such as ulcerative colitis for BPC-157, is what would allow a pharmacy to compound a substance, after which prescribers could use it off-label. She gives the public docket number FDA-2025-N-6895, open for comment until July 9th, and promotes her own peptide course.
On each compound
BPC-1575:40
Froese says the committee will evaluate BPC-157 for ulcerative colitis and gut healing. She says that once a pharmacy can legally make it, prescribers could still use it off-label for things like tendon tears or inflammatory conditions.
See how your DNA reads BPC-157TB-5005:40
According to Froese, TB-500 is on the July committee agenda for wound healing.
See how your DNA reads TB-500KPV5:40
Froese describes KPV as an anti-inflammatory peptide that the committee will evaluate for wound healing and inflammatory conditions.
See how your DNA reads KPVMOTS-c5:40
She says MOTS-c is being reviewed for obesity and osteoporosis, which she notes is not why people use it. She attributes the choice to published preclinical data on bone loss and on weight gain with a high-fat diet.
See how your DNA reads MOTS-cSemax6:10
Froese says Semax is being evaluated for cerebral ischemia or stroke, migraines and trigeminal neuralgia.
See how your DNA reads SemaxDSIP6:41
Froese says DSIP is being evaluated for opioid withdrawal, chronic insomnia and narcolepsy. She points to a study of DSIP in people withdrawing from opioids that she covers in her course.
See how your DNA reads DSIPMelanotan II7:12
Froese says Melanotan II is scheduled for review in February 2027 and that she does not understand its inclusion, citing case studies of people who developed melanoma weeks after trying it.
See how your DNA reads Melanotan II“removed from category 2 is not the same as okay to compound yet”
What this video doesn’t settle
- The video does not say how common low-purity research peptides actually are, and Froese herself says the extent is unknown.
- It reports only the planned committee agendas, not any committee vote, rulemaking outcome or date when pharmacies could legally compound these substances.
- Froese describes what the peptides are being reviewed for but does not present evidence that any of them works for those uses beyond brief mentions of preclinical data and one study.
Questions this video answers
Can pharmacies compound BPC-157 now that the FDA removed it from category 2?
Froese says no, not on this change alone. She says removal from category 2 is not the same as approval to compound, and a pharmacy that says otherwise is a red flag.
What did the FDA change for peptides on April 15, 2026?
Froese says the FDA removed 11 peptides and 12 compounds overall from the category 2 do not compound list. She says they now sit in regulatory limbo until the advisory committee reviews them.
When will the FDA advisory committee review BPC-157 and other peptides?
According to Froese, the Pharmacy Compounding Advisory Committee meets at the end of July 2026 for BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and DSIP. Melanotan II, Dihexa, LL-37 and injectable GHK copper follow in February 2027.
Why does Dr. Froese call the peptide market the wild west?
She says research peptide sellers face no testing or sterility rules like pharmacies do, and that some did not batch test often. She adds that the label is about unregulated supply, not necessarily that peptides are dangerous.
How can the public comment on the FDA peptide docket?
Froese says docket FDA-2025-N-6895 is open for comment until July 9th, with submissions at regulations.gov. She says reported outcomes from using these compounds matter to the committee.
Video by This Is Not Covered - Dr. Ashley Froese on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
